We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFMD
101
DELISTED
Affimed
AFMD
$588K ﹤0.01%
20,000
– –
EVFM
102
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$514K ﹤0.01%
+6,803
New +$522K
VIRX
103
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$401K ﹤0.01%
15,905
– –
AQST icon
104
Aquestive Therapeutics
AQST
$455M
$317K ﹤0.01%
99,600
– –
DVAX
105
DELISTED
Dynavax Technologies
DVAX
$268K ﹤0.01%
75,000
– –
TRIL
106
DELISTED
Trillium Therapeutics Inc.
TRIL
$155K ﹤0.01%
505,262
– –
AIXC
107
AIxCrypto Holdings Inc
AIXC
$13.7M
$87K ﹤0.01%
22
– –
RNTX
108
Rein Therapeutics
RNTX
$65.6M
– –
-102,000
Closed -$1.47M
ARRY
109
DELISTED
Array Biopharma Inc
ARRY
– –
-2,848,567
Closed -$132M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Baker Bros. Advisors held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Baker Bros. Advisors's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Baker Bros. Advisors fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 2 in Q3 2019.
  • Baker Bros. Advisors's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.